Home Transmembrane Transporters Chloride Channel activator Lubiprostone For research use only.

Lubiprostone

Synonyms: RU 0211,SPI-0211

Lubiprostone (RU 0211,SPI-0211) is an activator of ClC-2 chloride channels, used in the management of idiopathic chronic constipation.

Lubiprostone Chemical Structure

Lubiprostone Chemical Structure

CAS No. 136790-76-6

Purity & Quality Control

Lubiprostone Related Products

Biological Activity

Description Lubiprostone (RU 0211,SPI-0211) is an activator of ClC-2 chloride channels, used in the management of idiopathic chronic constipation.
Targets
ClC-2 chloride channels [1]
In vitro
In vitro

Lubiprostone induces a robust secretory response in T84 monolayers. Lubiprostone induces a rise in cAMP levels that was sensitive to EP(4)-receptor blockage in T84 cells. [1] Lubiprostone induces a contraction in rat and human stomach longitudinal muscle, which is inhibited by pretreatment with the EP(1) receptor antagonist but not by the EP(3) or EP(4) receptor antagonists. Lubiprostone also reduces electrically stimulated, neuronal contractions in rat and human colon circular muscle preparations. [2] Lubiprostone (1 mM) stimulates higher elevations in TER despite lower I(sc) responses compared with the nonselective secretory agonist PGE(2) (1 mM). Lubiprostone significantly reduces mucosal-to-serosal fluxes of (3)H-labeled mannitol to levels comparable to those of normal control tissues and restored occludin localization to tight junctions. [3] Lubiprostone causes comparable and maximal increases of I(sc) in T84 cells. Lubiprostone-induced increases in iodide efflux are ~80% of those obtained with forskolin. Lubiprostone activates Cl(-) secretion in T84 cells via cAMP, protein kinase A, and by increasing apical membrane CFTR protein. [4] Lubiprostone, applied to the small intestinal mucosa in eight concentrations ranging from 1-3000 nM, evokes increases in Isc in a concentration-dependent manner with an EC50 of 42.5 nM. Lubiprostone applied to the mucosa of the colon in eight concentrations ranging from 1-3000 nM evokes increases in Isc in a concentration-dependent manner with an EC50 of 31.7 nM. [5]
In Vivo
In vivo

Lubiprostone induces a CdCl(2)-insensitive secretory response in mouse intestine, but fail to induce intestinal Cl(-) secretion in Cftr-null mice. [1]
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT01469819 Completed
Chronic Idiopathic Constipation
Texas Tech University Health Sciences Center El Paso|Takeda Pharmaceuticals North America Inc.
 June 2012 Phase 2|Phase 3
NCT01324284 Completed
Colorectal Carcinoma
Asian Institute of Gastroenterology India
 March 2011 Phase 3
NCT00934479 Completed
Other Constipation|Irritable Bowel Syndrome
Mayo Clinic|Arizona State University|Takeda Pharmaceuticals North America Inc.
 April 2010 Phase 1
NCT01085643 Completed
Constipation-predominant Irritable Bowel Syndrome
Cedars-Sinai Medical Center|Takeda Pharmaceuticals North America Inc.
 March 2010 Not Applicable
NCT00985569 Withdrawn
Constipation
Synergy Health Solutions
 November 2009 --

Chemical Information & Solubility

Molecular Weight 390.46 Formula

C20H32F2O5
CAS No. 136790-76-6 SDF Download Lubiprostone SDF
Smiles CCCCC(C1(CCC2C(O1)CC(=O)C2CCCCCCC(=O)O)O)(F)F
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 78 mg/mL ( (199.76 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 78 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Lubiprostone | Lubiprostone ic50 | Lubiprostone price | Lubiprostone cost | Lubiprostone solubility dmso | Lubiprostone purchase | Lubiprostone manufacturer | Lubiprostone research buy | Lubiprostone order | Lubiprostone mouse | Lubiprostone chemical structure | Lubiprostone mw | Lubiprostone molecular weight | Lubiprostone datasheet | Lubiprostone supplier | Lubiprostone in vitro | Lubiprostone cell line | Lubiprostone concentration | Lubiprostone nmr